{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:54:44Z","timestamp":1792083284106,"version":"4.4.0"},"reference-count":328,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cca.2025.120772","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:04:12Z","timestamp":1764979452000},"page":"120772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials"],"prefix":"10.1016","volume":"581","author":[{"given":"Haniyeh","family":"Barzgar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darmadi","family":"Darmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jabbarova","family":"Nafisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxrob","family":"Narkulov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria B.","family":"Sviridova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.cca.2025.120772_bb0005","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMp2029646","article-title":"Solving population-wide obesity-progress and future prospects","volume":"383","author":"Kumanyika","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2025.120772_bb0010","article-title":"Food products quality and nutrition in relation to public. Balancing health and disease","volume":"25","author":"Aljerf","year":"2023","journal-title":"Prog. Nutr."},{"issue":"8","key":"10.1016\/j.cca.2025.120772_bb0015","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41366-023-01325-1","article-title":"Obesity-related complications, healthcare resource use and weight loss strategies in six European countries: the RESOURCE survey","volume":"47","author":"Evans","year":"2023","journal-title":"Int. J. Obes."},{"issue":"10","key":"10.1016\/j.cca.2025.120772_bb0020","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1038\/s41591-025-03765-w","article-title":"Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO)","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb0025","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2337\/dc06-2544","article-title":"Effect of BMI on lifetime risk for diabetes in the U.S","volume":"30","author":"Narayan","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cca.2025.120772_bb0030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.microc.2017.03.001","article-title":"Characterization and validation of candidate reference methods for the determination of calcium and magnesium in biological fluids","volume":"132","author":"Aljerf","year":"2017","journal-title":"Microchem. J."},{"key":"10.1016\/j.cca.2025.120772_bb0035","doi-asserted-by":"crossref","first-page":"9596202","DOI":"10.1155\/2017\/9596202","article-title":"Salivary distinctiveness and modifications in males with diabetes and beh\u00e7et\u2019s disease","volume":"2017","author":"Aljerf","year":"2017","journal-title":"Biochem. Res. Int."},{"issue":"10481","key":"10.1016\/j.cca.2025.120772_bb0040","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","author":"Ng","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2025.120772_bb0045","doi-asserted-by":"crossref","unstructured":"Yi X, Yang Y, Li T, Li M, Yao T, Hu G, et al. Signaling metabolite \u03b2-aminoisobutyric acid as a metabolic regulator, biomarker, and potential exercise pill. Front. Endocrinol. 2023;Volume 14 - 2023. https:\/\/doi.org\/10.3389\/fendo.2023.1192458.","DOI":"10.3389\/fendo.2023.1192458"},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0050","doi-asserted-by":"crossref","first-page":"29694","DOI":"10.1038\/s41598-025-13254-2","article-title":"Risk of major adverse cardiovascular events and all-cause mortality in type 2 diabetic patients receiving insulin versus non-insulin treatment intensification","volume":"15","author":"Lin","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0055","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12916-020-01688-6","article-title":"Insulin: too much of a good thing is bad","volume":"18","author":"Kolb","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.cca.2025.120772_bb0060","first-page":"79","article-title":"Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis","author":"Liu","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb0065","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41366-025-01729-1","article-title":"Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions","volume":"49","author":"Subramaniyan","year":"2025","journal-title":"Int. J. Obes."},{"issue":"14","key":"10.1016\/j.cca.2025.120772_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e34837","article-title":"Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database","volume":"10","author":"Zhu","year":"2024","journal-title":"Heliyon"},{"issue":"20","key":"10.1016\/j.cca.2025.120772_bb0075","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0080","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0085","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb0090","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/dom.15393","article-title":"Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study)","volume":"26","author":"Furusawa","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb0095","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/dom.15386","article-title":"Efficacy and safety of semaglutide 2.4mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial","volume":"26","author":"Qin","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"7","key":"10.1016\/j.cca.2025.120772_bb0100","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S2213-8587(19)30182-2","article-title":"Pioneering oral peptide therapy for patients with type 2 diabetes","volume":"7","author":"Nauck","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0105","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/acs.jmedchem.7b00318","article-title":"The current state of peptide drug discovery: back to the future?","volume":"61","author":"Henninot","year":"2018","journal-title":"J. Med. Chem."},{"issue":"S3","key":"10.1016\/j.cca.2025.120772_bb0110","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/dia.2023.0438","article-title":"The health economics of automated insulin delivery systems and the potential use of time in range in diabetes modeling: a narrative review","volume":"26","author":"Mathieu","year":"2024","journal-title":"Diabetes Technol. Ther."},{"issue":"11","key":"10.1016\/j.cca.2025.120772_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115131","article-title":"Therapeutic peptides: recent advances in discovery, synthesis, and clinical translation","volume":"26","author":"Zheng","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.cca.2025.120772_bb0120","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1097\/01.aids.0000247570.11128.ab","article-title":"Successful desensitization of enfuvirtide after a first attempt failure","volume":"20","author":"Machado","year":"2006","journal-title":"Aids"},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12981-016-0101-3","article-title":"Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial","volume":"13","author":"De Castro","year":"2016","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.cca.2025.120772_bb0130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neuropharm.2016.10.016","article-title":"Block of voltage-gated calcium channels by peptide toxins","volume":"127","author":"Bourinet","year":"2017","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.cca.2025.120772_bb0135","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1586\/14779072.2015.1054810","article-title":"Liraglutide for Type 2 diabetes and obesity: a 2015 update","volume":"13","author":"Iepsen","year":"2015","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101888","article-title":"Treatment of acromegaly with oral octreotide","volume":"38","author":"Remba-Shapiro","year":"2024","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb0145","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.apsb.2021.03.040","article-title":"HYD-PEP06 suppresses hepatocellular carcinoma metastasis, epithelial\u2013mesenchymal transition and cancer stem cell-like properties by inhibiting PI3K\/AKT and WNT\/\u03b2-catenin signaling activation","volume":"11","author":"Tian","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0150","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s12276-023-00958-6","article-title":"Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db\/db mice","volume":"55","author":"Pham","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"8","key":"10.1016\/j.cca.2025.120772_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70287","article-title":"Peptide Drug: Design and Clinical Applications","volume":"6","author":"Han","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.cca.2025.120772_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2021.102880","article-title":"The application progress of peptides in drug delivery systems in the past decade","volume":"66","author":"Yang","year":"2021","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0170","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","article-title":"Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cca.2025.120772_bb0175","first-page":"75","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","author":"Alfaris","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0180","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13679-025-00623-1","article-title":"Dual and triple gut peptide agonists on the horizon for the treatment of type 2 diabetes and obesity. an overview of preclinical and clinical data","volume":"14","author":"Anastasiou","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.cca.2025.120772_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114904","article-title":"Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems","volume":"199","author":"Shi","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0190","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in oral peptide therapeutics","volume":"19","author":"Drucker","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25020815","article-title":"The current and promising oral delivery methods for protein- and peptide-based drugs","volume":"25","author":"Nicze","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2025.120772_bb0200","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.nbt.2019.02.004","article-title":"Cost-effective production of recombinant peptides in Escherichia coli","volume":"51","author":"Gaglione","year":"2019","journal-title":"New Biotechnol."},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb0205","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nchembio.2318","article-title":"A fully automated flow-based approach for accelerated peptide synthesis","volume":"13","author":"Mijalis","year":"2017","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cca.2025.120772_bb0215","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdi.12466","article-title":"Is GLP-1 a hormone: Whether and When?","volume":"7","author":"D\u2019Alessio","year":"2016","journal-title":"J. Diabetes Investig."},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb0220","first-page":"1171","article-title":"GLP-1, a powerful physiological incretin: an update","volume":"32","author":"Malik","year":"2018","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.cca.2025.120772_bb0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/B978-0-12-800101-1.00002-8","article-title":"Regulation of glucose homeostasis by GLP-1","volume":"121","author":"Nadkarni","year":"2014","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0230","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.cca.2025.120772_bb0235","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes. Obes. Metab."},{"issue":"11","key":"10.1016\/j.cca.2025.120772_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113326","article-title":"GLP-1 and GIP receptors signal through distinct \u03b2-arrestin 2-dependent pathways to regulate pancreatic \u03b2 cell function","volume":"42","author":"Za\u00efmia","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.cca.2025.120772_bb0245","article-title":"GLP-1R in diabetes mellitus: from basic discovery to therapeutics development","volume":"16","author":"Li","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cca.2025.120772_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104896","article-title":"Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions","volume":"142","author":"Bhalla","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"12","key":"10.1016\/j.cca.2025.120772_bb0255","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.2337\/db14-0153","article-title":"GABA promotes human \u03b2-cell proliferation and modulates glucose homeostasis","volume":"63","author":"Purwana","year":"2014","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb0260","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2337\/db12-1013","article-title":"\u03b2-Cell\u2013specific protein kinase A activation enhances the efficiency of glucose control by increasing acute-phase insulin secretion","volume":"62","author":"Kaihara","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.cca.2025.120772_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216179","article-title":"Glucose transporter 4: Insulin response mastermind, glycolysis catalyst and treatment direction for cancer progression","volume":"563","author":"Chang","year":"2023","journal-title":"Cancer Lett."},{"issue":"26","key":"10.1016\/j.cca.2025.120772_bb0270","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1021\/acs.jafc.5b01238","article-title":"Effects of D-pinitol on insulin resistance through the PI3K\/Akt signaling pathway in type 2 diabetes mellitus rats","volume":"63","author":"Gao","year":"2015","journal-title":"J. Agric. Food Chem."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb0275","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2015.122","article-title":"Regulation of glucose metabolism from a liver-centric perspective","volume":"48","author":"Han","year":"2016","journal-title":"Exp. Mol. Med."},{"issue":"10","key":"10.1016\/j.cca.2025.120772_bb0280","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1210\/en.2010-0289","article-title":"Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance","volume":"151","author":"Ayala","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.cca.2025.120772_bb0285","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3389\/fphar.2018.01168","article-title":"GLP-1 improves adipocyte insulin sensitivity following induction of endoplasmic reticulum stress","volume":"9","author":"Jiang","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0290","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12967-016-0985-7","article-title":"The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism","volume":"14","author":"Andreozzi","year":"2016","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0295","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1038\/s41598-023-36178-1","article-title":"A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss","volume":"13","author":"Chichura","year":"2023","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.cca.2025.120772_bb0300","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1159\/000512806","article-title":"Glucagon-like peptide-1 regulates the proopiomelanocortin neurons of the arcuate nucleus both directly and indirectly via presynaptic action","volume":"111","author":"P\u00e9terfi","year":"2021","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.cca.2025.120772_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.665537","article-title":"The insulin response to oral glucose in GIP and GLP-1 receptor knockout mice: review of the literature and stepwise glucose dose response studies in female mice","volume":"12","author":"Ahr\u00e9n","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0310","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41387-024-00343-w","article-title":"Impaired brain glucose metabolism in glucagon-like peptide-1 receptor knockout mice","volume":"14","author":"Li","year":"2024","journal-title":"Nutr. Diabetes"},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb0315","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/00207454.2021.1924707","article-title":"The pleiotropic of GLP-1\/GLP-1R axis in central nervous system diseases","volume":"133","author":"Zhang","year":"2023","journal-title":"Int. J. Neurosci."},{"issue":"7","key":"10.1016\/j.cca.2025.120772_bb0320","doi-asserted-by":"crossref","DOI":"10.4239\/wjd.v16.i7.105233","article-title":"Exploring the link: Hemogram-derived markers in type 2 diabetes mellitus and its complications","volume":"16","author":"Aktas","year":"2025","journal-title":"World J. Diabetes"},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb0325","first-page":"145","article-title":"A novel marker for prediabetic conditions: Uric acid-to-HDL cholesterol ratio","volume":"125","author":"Balci","year":"2024","journal-title":"Bratisl. Lek. Listy"},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb0330","first-page":"111","article-title":"Evaluation of the effects of intermittent fasting on clinical and laboratory parameters in metabolic syndrome","volume":"8","author":"Taslamacioglu Duman","year":"2025","journal-title":"Exp. Biomed. Res."},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0335","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.516","article-title":"Inflammation in diabetes complications: molecular mechanisms and therapeutic interventions","volume":"5","author":"Zhao","year":"2024","journal-title":"MedComm"},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb0340","doi-asserted-by":"crossref","first-page":"47","DOI":"10.63623\/8cv4gh26","article-title":"A scoping review on recent advances in antidiabetic medications: from GLP-1 receptor agonists to dual and triple agonists","volume":"2","author":"Aktas","year":"2025","journal-title":"Ad. Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.cca.2025.120772_bb0345","doi-asserted-by":"crossref","first-page":"1446468","DOI":"10.3389\/fcvm.2024.1446468","article-title":"Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review","volume":"11","author":"Skrobucha","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0350","first-page":"3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0355","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12933-022-01686-3","article-title":"Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms","volume":"21","author":"Verg\u00e8s","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb0360","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jdiacomp.2014.12.006","article-title":"Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide","volume":"29","author":"Kuhre","year":"2015","journal-title":"J. Diabetes Complicat."},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb0365","doi-asserted-by":"crossref","first-page":"G608","DOI":"10.1152\/ajpgi.00024.2010","article-title":"Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut","volume":"298","author":"Fujita","year":"2010","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"10","key":"10.1016\/j.cca.2025.120772_bb0370","doi-asserted-by":"crossref","DOI":"10.1097\/MCG.0000000000000149","article-title":"Obesity and the gastrointestinal tract: you are what you eat","volume":"48","author":"Wolfe","year":"2014","journal-title":"J. Clin. Gastroenterol."},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb0375","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.pbiomolbio.2011.07.010","article-title":"Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and \u03b2 cell preservation","volume":"107","author":"Yabe","year":"2011","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.cca.2025.120772_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170196","article-title":"Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors","volume":"125","author":"Deacon","year":"2020","journal-title":"Peptides"},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb0390","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/endo.133.6.8243312","article-title":"Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain","volume":"133","author":"Usdin","year":"1993","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb0395","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.2040-1124.2012.00196.x","article-title":"Glucose-dependent insulinotropic polypeptide signaling in pancreatic \u03b2-cells and adipocytes","volume":"3","author":"McIntosh","year":"2012","journal-title":"J. Diabetes Investig."},{"issue":"49","key":"10.1016\/j.cca.2025.120772_bb0400","doi-asserted-by":"crossref","first-page":"46046","DOI":"10.1074\/jbc.M108378200","article-title":"Critical role of cAMP-GEFII\u00b7 Rim2 complex in incretin-potentiated insulin secretion","volume":"276","author":"Kashima","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.cca.2025.120772_bb0405","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/oby.2008.393","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) stimulates transepithelial glucose transport","volume":"16","author":"Singh","year":"2008","journal-title":"Obesity"},{"issue":"10","key":"10.1016\/j.cca.2025.120772_bb0410","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00098.2013","article-title":"Glucose-dependent insulinotropic polypeptide regulates dipeptide absorption in mouse jejunum","volume":"305","author":"Coon","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"10","key":"10.1016\/j.cca.2025.120772_bb0415","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164921","article-title":"Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding","volume":"8","author":"Adriaenssens","year":"2023","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.cca.2025.120772_bb0420","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","article-title":"Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice","volume":"5","author":"Liskiewicz","year":"2023","journal-title":"Nat Metab."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb0425","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0167-0115(93)90362-C","article-title":"Cosecretion of islet amylid polypeptide (IAPP) and insulin from isolated rat pancreatic islets following stimulation or inhibition of \u03b2-cell function","volume":"45","author":"Stridsberg","year":"1993","journal-title":"Regul. Pept."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb0430","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0435","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/00365529609031632","article-title":"Effects of acute and chronic infusion of islet amyloid polypeptide on food intake in rats","volume":"31","author":"Arnelo","year":"1996","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.cca.2025.120772_bb0440","series-title":"Calcitonin receptors in GtoPdb v. 2023.1. IUPHAR\/BPS Guide to Pharmacology CITE","author":"Garelja","year":"2023"},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0445","article-title":"Endogenous VMH amylin signaling is required for full leptin signaling and protection from diet-induced obesity","volume":"310","author":"Dunn-Meynell","year":"2016","journal-title":"Am. J. Phys. Regul. Integr. Comp. Phys."},{"key":"10.1016\/j.cca.2025.120772_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107987","article-title":"Salmon calcitonin distributes into the arcuate nucleus to a subset of NPY neurons in mice","volume":"167","author":"Zakariassen","year":"2020","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0455","doi-asserted-by":"crossref","first-page":"320","DOI":"10.7570\/jomes21071","article-title":"Amylin as a future obesity treatment","volume":"30","author":"Dehestani","year":"2021","journal-title":"J. Obes. Metab. Syndr."},{"key":"10.1016\/j.cca.2025.120772_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177593","article-title":"The protective effect of amylin in type 2 diabetes: Yes or no","volume":"996","author":"Alanazi","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.cca.2025.120772_bb0465","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11082207","article-title":"Mediators of amylin action in metabolic control","volume":"11","author":"Boyle","year":"2022","journal-title":"J. Clin. Med."},{"issue":"1 Suppl","key":"10.1016\/j.cca.2025.120772_bb0470","first-page":"47s","article-title":"Role of amylin in Type 1 and Type 2 diabetes","volume":"41","author":"Hieronymus","year":"2015","journal-title":"Diabetes Educ."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb0475","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/bcpt.13427","article-title":"Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases","volume":"127","author":"Zakariassen","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0480","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.physbeh.2004.01.006","article-title":"Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats","volume":"81","author":"Mollet","year":"2004","journal-title":"Physiol. Behav."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb0485","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.appet.2010.04.164","article-title":"Amylin induces ERK 1\/2 phosphorylation in structures of the AP\/NTS-LPB-Ce-BSTL axis","volume":"54","author":"Potes","year":"2010","journal-title":"Appetite"},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb0490","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0304-3940(02)00482-2","article-title":"Amylin and glucose co-activate area postrema neurons of the rat","volume":"328","author":"Riediger","year":"2002","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0495","article-title":"The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis","volume":"286","author":"Riediger","year":"2004","journal-title":"Am. J. Phys. Regul. Integr. Comp. Phys."},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb0500","first-page":"R1475","article-title":"The role of amylin in the control of energy homeostasis","volume":"298","author":"Lutz","year":"2010","journal-title":"Am. J. Phys. Regul. Integr. Comp. Phys."},{"issue":"7","key":"10.1016\/j.cca.2025.120772_bb0505","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1210\/en.2012-2172","article-title":"Amylin acts in the central nervous system to increase sympathetic nerve activity","volume":"154","author":"Fernandes-Santos","year":"2013","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.cca.2025.120772_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108592","article-title":"Brown adipose tissue: a new potential target for glucagon-like peptide 1 receptor agonists in the treatment of obesity","volume":"24","author":"Hropot","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0515","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41467-020-15717-8","article-title":"Paracrine control of \u03b1-cell glucagon exocytosis is compromised in human type-2 diabetes","volume":"11","author":"Omar-Hmeadi","year":"2020","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.cca.2025.120772_bb0520","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s40279-021-01473-2","article-title":"The effect of a single bout of continuous aerobic exercise on glucose, insulin and glucagon concentrations compared to resting conditions in healthy adults: a systematic review, meta-analysis and meta-regression","volume":"51","author":"Frampton","year":"2021","journal-title":"Sports Med."},{"issue":"18","key":"10.1016\/j.cca.2025.120772_bb0525","doi-asserted-by":"crossref","DOI":"10.3390\/nu15183913","article-title":"The regulation and secretion of glucagon in response to nutrient composition: unraveling their intricate mechanisms","volume":"15","author":"Zhang","year":"2023","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb0530","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The new biology and pharmacology of glucagon","volume":"97","author":"M\u00fcller","year":"2017","journal-title":"Physiol. Rev."},{"issue":"8","key":"10.1016\/j.cca.2025.120772_bb0535","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081907","article-title":"Insights into the role of glucagon receptor signaling in metabolic regulation from pharmacological inhibition and tissue-specific knockout models","volume":"10","author":"Lasher","year":"2022","journal-title":"Biomedicines"},{"issue":"13","key":"10.1016\/j.cca.2025.120772_bb0540","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133314","article-title":"Glucagon receptor signaling and glucagon resistance","volume":"20","author":"Janah","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"7564","key":"10.1016\/j.cca.2025.120772_bb0545","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature14557","article-title":"The CREB coactivator CRTC2 controls hepatic lipid metabolism by regulating SREBP1","volume":"524","author":"Han","year":"2015","journal-title":"Nature"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2025.120772_bb0550","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1463-1326.2011.01454.x","article-title":"Physiologic action of glucagon on liver glucose metabolism","volume":"13","author":"Ramnanan","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.cca.2025.120772_bb0555","first-page":"45","article-title":"Metabolic effects of glucagon in humans","volume":"15","author":"Adeva-Andany","year":"2019","journal-title":"J. Clin. Transl. Endocrinol."},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102838","article-title":"Regulation and function of the mammalian tricarboxylic acid cycle","volume":"299","author":"Arnold","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.cca.2025.120772_bb0565","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/iub.375","article-title":"Amino acid ingestion and glucose metabolism\u2014a review","volume":"62","author":"Gannon","year":"2010","journal-title":"IUBMB Life"},{"issue":"12","key":"10.1016\/j.cca.2025.120772_bb0570","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1210\/jc.2015-2335","article-title":"Effect of oxyntomodulin, glucagon, GLP-1, and combined glucagon +GLP-1 infusion on food intake, appetite, and resting energy expenditure","volume":"100","author":"Bagger","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.cca.2025.120772_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2025.104213","article-title":"Next generation dual GLP-1\/GIP, GLP-1\/glucagon, and triple GLP-1\/GIP\/glucagon agonists: a literature review","volume":"35","author":"Wen","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"9","key":"10.1016\/j.cca.2025.120772_bb0580","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1111\/dom.15693","article-title":"Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity","volume":"26","author":"Winther","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"17","key":"10.1016\/j.cca.2025.120772_bb0585","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"19","key":"10.1016\/j.cca.2025.120772_bb0590","doi-asserted-by":"crossref","first-page":"20765","DOI":"10.1021\/acs.jmedchem.5c02032","article-title":"Strategic design of triple GLP-1R\/GCGR\/GIPR agonists with varied receptor potency: achieving comparable glycemic and weight reduction effects","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb0595","article-title":"Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R\/GIPR biased agonism yielding greater efficacy","volume":"6","author":"Rodriguez","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.cca.2025.120772_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171003","article-title":"The molecular pharmacology of glucagon agonists in diabetes and obesity","volume":"165","author":"Novikoff","year":"2023","journal-title":"Peptides"},{"key":"10.1016\/j.cca.2025.120772_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114150","article-title":"Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors","volume":"180","author":"Darbalaei","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb0610","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264974","article-title":"Preclinical evaluation of a protracted GLP-1\/glucagon receptor co-agonist: Translational difficulties and pitfalls","volume":"17","author":"Simonsen","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb0615","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s13300-024-01566-x","article-title":"Dual and triple incretin-based co-agonists: novel therapeutics for obesity and diabetes","volume":"15","author":"Gutgesell","year":"2024","journal-title":"Diabetes Ther."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb0620","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1021\/acs.accounts.1c00560","article-title":"How do biomolecules cross the cell membrane?","volume":"55","author":"Pei","year":"2022","journal-title":"Acc. Chem. Res."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb0625","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s11095-023-03486-0","article-title":"Strategies to improve the physicochemical properties of peptide-based drugs","volume":"40","author":"Lee","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.cca.2025.120772_bb0630","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jconrel.2021.01.015","article-title":"Replacement of L-amino acid peptides with D-amino acid peptides mitigates anti-PEG antibody generation against polymer-peptide conjugates in mice","volume":"331","author":"Sylvestre","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.cca.2025.120772_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106892","article-title":"Backbone N-methylation of peptides: Advances in synthesis and applications in pharmaceutical drug development","volume":"141","author":"Li","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0640","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3225","article-title":"Incorporation of \u03b2-amino acids into ascidiacyclamides: Effects on conformation, cytotoxicity and interaction with copper (II) ion","volume":"26","author":"Asano","year":"2020","journal-title":"J. Pept. Sci."},{"issue":"28","key":"10.1016\/j.cca.2025.120772_bb0645","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.2174\/138161210793292555","article-title":"Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization","volume":"16","author":"Gentilucci","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb0650","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10989-024-10639-1","article-title":"Unlocking the potential of retro-inverso (RI) PEPTIDES AS FUTURE DRUG CANDIDATES","volume":"30","author":"Al","year":"2024","journal-title":"Int. J. Pept. Res. Ther."},{"issue":"16","key":"10.1016\/j.cca.2025.120772_bb0655","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168677","article-title":"Recent applications of retro-inverso peptides","volume":"22","author":"Doti","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb0665","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/cbic.201700580","article-title":"Evaluation of \u03b2-amino acid replacements in protein loops: effects on conformational stability and structure","volume":"19","author":"Mortenson","year":"2018","journal-title":"Chembiochem"},{"issue":"27","key":"10.1016\/j.cca.2025.120772_bb0670","doi-asserted-by":"crossref","first-page":"9151","DOI":"10.1073\/pnas.0801135105","article-title":"Interplay among side chain sequence, backbone composition, and residue rigidification in polypeptide folding and assembly","volume":"105","author":"Horne","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.cca.2025.120772_bb0675","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1021\/ja0667965","article-title":"Cyclic modular \u03b2-sheets","volume":"129","author":"Woods","year":"2007","journal-title":"J. Am. Chem. Soc."},{"issue":"9","key":"10.1016\/j.cca.2025.120772_bb0680","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1529\/biophysj.106.084491","article-title":"Thermodynamic stability of beta-peptide helices and the role of cyclic residues","volume":"91","author":"Rathore","year":"2006","journal-title":"Biophys. J."},{"key":"10.1016\/j.cca.2025.120772_bb0685","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cbpa.2015.06.013","article-title":"Folding and function in \u03b1\/\u03b2-peptides: targets and therapeutic applications","volume":"28","author":"Werner","year":"2015","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"42","key":"10.1016\/j.cca.2025.120772_bb0690","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.2174\/0929867329666220510214402","article-title":"Azapeptides-A history of synthetic milestones and key Examples","volume":"29","author":"Fan Cheng","year":"2022","journal-title":"Curr. Med. Chem."},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb0695","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3384","article-title":"Different directions for retro-inverso peptides","volume":"28","author":"Preston","year":"2022","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.cca.2025.120772_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106686","article-title":"Recent advances in anticancer peptoids","volume":"139","author":"Zhu","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0705","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16040477","article-title":"Influence of aza-glycine substitution on the internalization of penetratin","volume":"16","author":"Tarchoun","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0710","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12951-017-0269-2","article-title":"A retro-inverso cell-penetrating peptide for siRNA delivery","volume":"15","author":"Vaissi\u00e8re","year":"2017","journal-title":"J. Nanobiotechnol."},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb0715","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1021\/ja0668623","article-title":"Quantitative evaluation of the relative cell permeability of peptoids and peptides","volume":"129","author":"Kwon","year":"2007","journal-title":"J. Am. Chem. Soc."},{"issue":"11","key":"10.1016\/j.cca.2025.120772_bb0720","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1016\/j.bmc.2008.04.074","article-title":"High-throughput evaluation of relative cell permeability between peptoids and peptides","volume":"16","author":"Tan","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"sup1","key":"10.1016\/j.cca.2025.120772_bb0725","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/21691401.2017.1414823","article-title":"Effects of N-terminal and C-terminal modification on cytotoxicity and cellular uptake of amphiphilic cell penetrating peptides","volume":"46","author":"Soleymani-Goloujeh","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.cca.2025.120772_bb0730","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijbiomac.2021.07.080","article-title":"The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy","volume":"187","author":"Tao","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0735","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/acs.jnatprod.7b00337","article-title":"Alveolarides: Antifungal peptides from Microascus alveolaris active against phytopathogenic fungi","volume":"81","author":"Fotso","year":"2018","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.cca.2025.120772_bb0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127925","article-title":"Use of homoarginine to obtain attenuated cationic membrane lytic peptides","volume":"40","author":"Sakamoto","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.cca.2025.120772_bb0745","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1021\/acs.orglett.0c00713","article-title":"Side-chain modification of peptides using a phosphoranylidene amino acid","volume":"22","author":"Masri","year":"2020","journal-title":"Org. Lett."},{"issue":"10370","key":"10.1016\/j.cca.2025.120772_bb0750","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0755","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-023-02273-z","article-title":"Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial","volume":"29","author":"Crees","year":"2023","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb0760","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"issue":"17","key":"10.1016\/j.cca.2025.120772_bb0765","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1021\/acs.jmedchem.0c00686","article-title":"Head-to-tail cyclization after interaction with trypsin: a scorpion venom peptide that resembles plant cyclotides","volume":"63","author":"Mour\u00e3o","year":"2020","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb0770","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1021\/acs.jmedchem.9b01811","article-title":"Binding loop substitutions in the cyclic peptide SFTI-1 generate potent and selective chymase inhibitors","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0775","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1021\/acs.chemrev.0c01087","article-title":"Elucidating solution structures of cyclic peptides using molecular dynamics simulations","volume":"121","author":"Damjanovic","year":"2021","journal-title":"Chem. Rev."},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0780","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1021\/acs.jmedchem.2c01837","article-title":"Lessons for oral bioavailability: how conformationally flexible cyclic peptides enter and cross lipid membranes","volume":"66","author":"Linker","year":"2023","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb0785","doi-asserted-by":"crossref","DOI":"10.3390\/md19060311","article-title":"Improvement on permeability of cyclic peptide\/peptidomimetic: backbone n-methylation as a useful tool","volume":"19","author":"Li","year":"2021","journal-title":"Mar. Drugs"},{"issue":"12","key":"10.1016\/j.cca.2025.120772_bb0790","doi-asserted-by":"crossref","first-page":"8094","DOI":"10.1021\/acs.chemrev.6b00838","article-title":"Orally absorbed cyclic peptides","volume":"117","author":"Nielsen","year":"2017","journal-title":"Chem. Rev."},{"issue":"18","key":"10.1016\/j.cca.2025.120772_bb0795","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1021\/acs.orglett.9b02592","article-title":"Stabilization of cyclic \u03b2-hairpins by ugi-reaction-derived N-alkylated peptides: the quest for functionalized \u03b2-turns","volume":"21","author":"Ricardo","year":"2019","journal-title":"Org. Lett."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0800","doi-asserted-by":"crossref","first-page":"2284685","DOI":"10.1080\/10717544.2023.2284685","article-title":"Lipidization as a tool toward peptide therapeutics","volume":"30","author":"My\u0161kov\u00e1","year":"2023","journal-title":"Drug Deliv."},{"issue":"17","key":"10.1016\/j.cca.2025.120772_bb0805","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.2174\/0929867325666181026100849","article-title":"Lipids as activators of innate immunity in peptide vaccine delivery","volume":"27","author":"Bartlett","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.cca.2025.120772_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2021.105053","article-title":"Opportunities and challenges of fatty acid conjugated therapeutics","volume":"236","author":"Bhat","year":"2021","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.cca.2025.120772_bb0815","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cbpa.2016.08.006","article-title":"How PEGylation influences protein conformational stability","volume":"34","author":"Lawrence","year":"2016","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"7","key":"10.1016\/j.cca.2025.120772_bb0820","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068559","article-title":"Molecular insight into the steric shielding effect of PEG on the conjugated staphylokinase: biochemical characterization and molecular dynamics simulation","volume":"8","author":"Mu","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0825","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00726-025-03454-5","article-title":"Therapeutic peptides: chemical strategies fortify peptides for enhanced disease treatment efficacy","volume":"57","author":"Li","year":"2025","journal-title":"Amino Acids"},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0830","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nchem.1230","article-title":"Drug delivery: Relieving PEGylation","volume":"4","author":"Parrott","year":"2011","journal-title":"Nat. Chem."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0835","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd3349","article-title":"Pegloticase","volume":"10","author":"Schlesinger","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0840","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1007\/s13346-024-01747-y","article-title":"Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies","volume":"15","author":"Nakmode","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb0845","doi-asserted-by":"crossref","DOI":"10.3390\/ph17010015","article-title":"A new approach for preparing stable high-concentration peptide nanoparticle formulations","volume":"17","author":"Hu","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cca.2025.120772_bb0850","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jddst.2015.05.002","article-title":"Particulate formulations based on chitosan for nose-to-brain delivery of drugs. A review","volume":"32","author":"Rassu","year":"2016","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.cca.2025.120772_bb0855","doi-asserted-by":"crossref","unstructured":"Omidian H, Wilson RL, Castejon AM. Recent Advances in Peptide-Loaded PLGA Nanocarriers for Drug Delivery and Regenerative Medicine. Pharmaceuticals. 2025; 18(1):[127 p.]. 10.3390\/ph18010127.","DOI":"10.3390\/ph18010127"},{"key":"10.1016\/j.cca.2025.120772_bb0860","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcis.2013.05.081","article-title":"Active drug encapsulation and release kinetics from hydrogel-in-liposome nanoparticles","volume":"406","author":"Wang","year":"2013","journal-title":"J. Colloid Interface Sci."},{"issue":"7","key":"10.1016\/j.cca.2025.120772_bb0865","doi-asserted-by":"crossref","DOI":"10.3390\/polym15071596","article-title":"Nanoparticles as drug delivery systems: a review of the implication of nanoparticles\u2019 physicochemical properties on responses in biological systems","volume":"15","author":"Yusuf","year":"2023","journal-title":"Polymers"},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb0870","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12060567","article-title":"Injectable lipid-based depot formulations: Where do we stand?","volume":"12","author":"Rahnfeld","year":"2020","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.cca.2025.120772_bb0875","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12100999","article-title":"Injectables and depots to prolong drug action of proteins and peptides","volume":"12","author":"Ibeanu","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2\u20133","key":"10.1016\/j.cca.2025.120772_bb0880","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb0885","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol. Immunol."},{"issue":"12","key":"10.1016\/j.cca.2025.120772_bb0890","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.addr.2011.06.017","article-title":"Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention","volume":"63","author":"Szebeni","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb0895","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2007.02.010","article-title":"Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes","volume":"119","author":"Wang","year":"2007","journal-title":"J. Control. Release"},{"issue":"24","key":"10.1016\/j.cca.2025.120772_bb0900","doi-asserted-by":"crossref","first-page":"6951","DOI":"10.1039\/D2BM01113A","article-title":"Sustained release of drug-loaded nanoparticles from injectable hydrogels enables long-term control of macrophage phenotype","volume":"10","author":"Soni","year":"2022","journal-title":"Biomater Sci."},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb0905","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/en.2009-1082","article-title":"Nanoparticles and the immune system","volume":"151","author":"Zolnik","year":"2010","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb0910","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/ALN.0b013e31816c8a48","article-title":"Local myotoxicity from sustained release of bupivacaine from microparticles","volume":"108","author":"Padera","year":"2008","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb0915","doi-asserted-by":"crossref","DOI":"10.3390\/nano10020190","article-title":"Immunological and Toxicological Considerations for the Design of Liposomes","volume":"10","author":"Inglut","year":"2020","journal-title":"Nanomaterials (Basel)"},{"issue":"4706","key":"10.1016\/j.cca.2025.120772_bb0920","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/185117a0","article-title":"Hydrophilic gels for biological use","volume":"185","author":"Wichterle","year":"1960","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.cca.2025.120772_bb0925","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1021\/acs.chemmater.9b00769","article-title":"In situ forming, dual-crosslink network, self-healing hydrogel enabled by a bioorthogonal nopoldiol\u2013benzoxaborolate click reaction with a wide pH range","volume":"31","author":"Wu","year":"2019","journal-title":"Chem. Mater."},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb0930","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1021\/cr200157d","article-title":"Hydrogels for protein delivery","volume":"112","author":"Vermonden","year":"2012","journal-title":"Chem. Rev."},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0935","doi-asserted-by":"crossref","DOI":"10.3390\/gels10040262","article-title":"Advances in hydrogel-based drug delivery systems","volume":"10","author":"Liu","year":"2024","journal-title":"Gels"},{"issue":"18","key":"10.1016\/j.cca.2025.120772_bb0940","doi-asserted-by":"crossref","first-page":"11385","DOI":"10.1021\/acs.chemrev.0c01177","article-title":"Translational applications of hydrogels","volume":"121","author":"Correa","year":"2021","journal-title":"Chem. Rev."},{"issue":"12","key":"10.1016\/j.cca.2025.120772_bb0945","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.71","article-title":"Designing hydrogels for controlled drug delivery","volume":"1","author":"Li","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.cca.2025.120772_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2025.106758","article-title":"Smart hydrogels and the promise of multi-responsive in-situ systems","volume":"107","author":"Jahanbekam","year":"2025","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"7","key":"10.1016\/j.cca.2025.120772_bb0955","doi-asserted-by":"crossref","DOI":"10.3390\/gels9070523","article-title":"Polymer-based hydrogels applied in drug delivery: An overview","volume":"9","author":"Thang","year":"2023","journal-title":"Gels"},{"issue":"11","key":"10.1016\/j.cca.2025.120772_bb0960","doi-asserted-by":"crossref","DOI":"10.3390\/gels10110693","article-title":"A review of advanced hydrogel applications for tissue engineering and drug delivery systems as biomaterials","volume":"10","author":"Choi","year":"2024","journal-title":"Gels"},{"key":"10.1016\/j.cca.2025.120772_bb0965","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2016.04.008","article-title":"D-amino acid-containing supramolecular nanofibers for potential cancer therapeutics","volume":"110-111","author":"Wang","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.cca.2025.120772_bb0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114097","article-title":"Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers","volume":"182","author":"Haddadzadegan","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.cca.2025.120772_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2022.102638","article-title":"Strategies for improving the safety and RNAi efficacy of noncovalent peptide\/siRNA nanocomplexes","volume":"302","author":"Wang","year":"2022","journal-title":"Adv. Colloid Interf. Sci."},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb0980","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1021\/acs.bioconjchem.0c00152","article-title":"Design strategies and medicinal applications of metal-peptidic bioconjugates","volume":"31","author":"Meier-Menches","year":"2020","journal-title":"Bioconjug. Chem."},{"issue":"18","key":"10.1016\/j.cca.2025.120772_bb0985","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1039\/D1OB00411E","article-title":"Approaches for peptide and protein cyclisation","volume":"19","author":"Hayes","year":"2021","journal-title":"Org. Biomol. Chem."},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0990","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17040397","article-title":"Barriers and strategies for oral peptide and protein therapeutics Delivery: update on clinical advances","volume":"17","author":"Baral","year":"2025","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb0995","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10989-023-10524-3","article-title":"Strategic approaches to improvise peptide drugs as next generation therapeutics","volume":"29","author":"Barman","year":"2023","journal-title":"Int. J. Pept. Res. Ther."},{"key":"10.1016\/j.cca.2025.120772_bb1000","doi-asserted-by":"crossref","unstructured":"Plum A, Jensen LB, Kristensen JB. In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis. J. Pharm. Sci. 2013;102(8):2882-8. https:\/\/doi.org\/10.1002\/jps.23648.","DOI":"10.1002\/jps.23648"},{"issue":"11","key":"10.1016\/j.cca.2025.120772_bb1005","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1124\/dmd.110.034066","article-title":"Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase","volume":"38","author":"Malm-Erjef\u00e4lt","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cca.2025.120772_bb1010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.12.032","article-title":"A review of lipidation in the development of advanced protein and peptide therapeutics","volume":"295","author":"Menacho-Melgar","year":"2019","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.cca.2025.120772_bb1015","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1021\/jm101357e","article-title":"Long-acting lipidated analogue of human pancreatic polypeptide is slowly released into circulation","volume":"54","author":"Bellmann-Sickert","year":"2011","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb1020","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11095-004-1189-z","article-title":"Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide","volume":"22","author":"Yuan","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.cca.2025.120772_bb1025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2025.107205","article-title":"Oral peptide delivery Systems: Synergistic approaches using polymers, lipids, Nanotechnology, and needle-based carriers","volume":"112","author":"Al Tahan","year":"2025","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"13","key":"10.1016\/j.cca.2025.120772_bb1030","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s40265-023-01925-1","article-title":"Insulin tregopil: an ultra-fast oral recombinant human insulin analog: preclinical and clinical development in diabetes mellitus","volume":"83","author":"Joshi","year":"2023","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.cca.2025.120772_bb1035","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17081074","article-title":"Anti-PEG antibodies and their biological impact on pegylated drugs: challenges and strategies for optimization","volume":"17","author":"Fu","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cca.2025.120772_bb1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119792","article-title":"PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production","volume":"588","author":"Suzuki","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb1045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/bc200551b","article-title":"Role of the methoxy group in immune responses to mPEG-protein conjugates","volume":"23","author":"Sherman","year":"2012","journal-title":"Bioconjug. Chem."},{"issue":"1\u20132","key":"10.1016\/j.cca.2025.120772_bb1050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijpharm.2013.01.012","article-title":"Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan","volume":"443","author":"Li","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.cca.2025.120772_bb1055","series-title":"Seminars in Arthritis and Rheumatism","article-title":"The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review","author":"Keenan","year":"2021"},{"key":"10.1016\/j.cca.2025.120772_bb1060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.08.017","article-title":"Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG","volume":"311","author":"McSweeney","year":"2019","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb1065","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41589-023-01496-y","article-title":"De novo development of small cyclic peptides that are orally bioavailable","volume":"20","author":"Merz","year":"2024","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.cca.2025.120772_bb1070","series-title":"StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Mayur Parmar declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2025","author":"Cerillo","year":"2025"},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb1075","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13300-016-0180-0","article-title":"Clinical effectiveness of liraglutide in Type 2 diabetes treatment in the real-world setting: a systematic literature review","volume":"7","author":"Ostawal","year":"2016","journal-title":"Diabetes Ther."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb1080","doi-asserted-by":"crossref","first-page":"2432462","DOI":"10.1080\/20523211.2024.2432462","article-title":"Long-Term clinical efficacy of liraglutide for type 2 diabetes: real-world evidence and outcomes from Pakistan","volume":"17","author":"Butt","year":"2024","journal-title":"J. Pharm. Policy Pract."},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb1085","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in Type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb1090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1545","article-title":"Liraglutide for lower limb perfusion in people with Type 2 diabetes and peripheral artery disease: The STARDUST randomized clinical trial","volume":"7","author":"Caruso","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.cca.2025.120772_bb1095","article-title":"Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)","volume":"351","author":"Lind","year":"2015","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.cca.2025.120772_bb1100","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamasurg.2023.2930","article-title":"Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: The BARI-OPTIMISE Randomized Clinical Trial","volume":"158","author":"Mok","year":"2023","journal-title":"JAMA Surg."},{"key":"10.1016\/j.cca.2025.120772_bb1105","series-title":"StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Philip Whitfield declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2025","author":"Kommu","year":"2025"},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb1110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.103024","article-title":"Efficacy and safety of oral semaglutide in type 2 diabetes: A systematic review of real-world evidence","volume":"18","author":"Singh","year":"2024","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"issue":"11","key":"10.1016\/j.cca.2025.120772_bb1120","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10278","key":"10.1016\/j.cca.2025.120772_bb1125","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cca.2025.120772_bb1130","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.cca.2025.120772_bb1135","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.cca.2025.120772_bb1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171149","article-title":"Recent advances in peptide-based therapies for obesity and type 2 diabetes","volume":"173","author":"Bailey","year":"2024","journal-title":"Peptides"},{"issue":"19","key":"10.1016\/j.cca.2025.120772_bb1145","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2025.120772_bb1150","doi-asserted-by":"crossref","first-page":"1293926","DOI":"10.3389\/fcdhc.2023.1293926","article-title":"The benefits of GLP1 receptors in cardiovascular diseases","volume":"4","author":"Ferhatbegovi\u0107","year":"2023","journal-title":"Front. Clin. Diabetes Healthc."},{"key":"10.1016\/j.cca.2025.120772_bb1155","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.cca.2025.120772_bb1160","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"issue":"Spec Feature","key":"10.1016\/j.cca.2025.120772_bb1165","first-page":"131","article-title":"Trulicity (Dulaglutide): a new GLP-1 receptor agonist once-weekly subcutaneous injection approved for the treatment of patients with Type 2 diabetes","volume":"8","author":"Fala","year":"2015","journal-title":"Am. Health Drug Benefits"},{"issue":"8","key":"10.1016\/j.cca.2025.120772_bb1170","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/dom.14058","article-title":"A glycosylated Fc-fused glucagon-like peptide-1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide","volume":"22","author":"An","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb1175","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)","volume":"44","author":"Frias","year":"2021","journal-title":"Diabetes Care"},{"issue":"10193","key":"10.1016\/j.cca.2025.120772_bb1180","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2025.120772_bb1185","series-title":"Trulicity\u00ae (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease","year":"2020"},{"key":"10.1016\/j.cca.2025.120772_bb1190","author":"Administration USFaD"},{"issue":"10","key":"10.1016\/j.cca.2025.120772_bb1195","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ejhf.2670","article-title":"Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial","volume":"24","author":"Branch","year":"2022","journal-title":"Eur. J. Heart Fail."},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb1200","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1177\/1932296815583059","article-title":"Safe and effective use of the once weekly dulaglutide single-dose pen in injection-na\u00efve patients with type 2 diabetes","volume":"9","author":"Matfin","year":"2015","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.cca.2025.120772_bb1205","series-title":"Endocrinology: Adult and Pediatric (Seventh Edition)","article-title":"Chapter 48 - management of type 2 diabetes mellitus","author":"Dungan","year":"2016"},{"key":"10.1016\/j.cca.2025.120772_bb1210","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.cca.2025.120772_bb1215","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","article-title":"A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes","volume":"29","author":"Edelman","year":"2006","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.cca.2025.120772_bb1220","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2337\/dc08-0029","article-title":"Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity","volume":"31","author":"Smith","year":"2008","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb1225","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s13300-025-01733-8","article-title":"Amylin: from mode of action to future clinical potential in diabetes and obesity","volume":"16","author":"Vol\u010dan\u0161ek","year":"2025","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.cca.2025.120772_bb1230","year":"2014","journal-title":"Food Drug Admin."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb1235","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.cca.2025.120772_bb1240","first-page":"13","article-title":"Clinical perspectives on the use of the GIP\/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity","author":"Gallwitz","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb1245","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10402","key":"10.1016\/j.cca.2025.120772_bb1250","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.cca.2025.120772_bb1255","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.cca.2025.120772_bb1260","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2025.120772_bb1265","doi-asserted-by":"crossref","unstructured":"Liu L, Cui J, Neidecker MV, Nahata MC. Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States. J Manag Care Spec Pharm. 2025;31(5):441-50. 10.18553\/jmcp.2025.31.5.441.","DOI":"10.18553\/jmcp.2025.31.5.441"},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb1270","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.cca.2025.120772_bb1275","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern. Med."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb1280","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb1285","doi-asserted-by":"crossref","first-page":"213","DOI":"10.12997\/jla.2023.12.3.213","article-title":"The cardiovascular effect of tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist","volume":"12","author":"Cho","year":"2023","journal-title":"J. Lipid Atheroscler."},{"issue":"Supplement_1","key":"10.1016\/j.cca.2025.120772_bb1290","doi-asserted-by":"crossref","DOI":"10.2337\/db25-103-OR","article-title":"103-OR: association of tirzepatide with kidney parameters in people with obesity and prediabetes from SURMOUNT-1 over 176 weeks","volume":"74","author":"Heerspink","year":"2025","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.cca.2025.120772_bb1295","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/oby.24332","article-title":"Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial","volume":"33","author":"Lam","year":"2025","journal-title":"Obesity (Silver Spring)"},{"issue":"9","key":"10.1016\/j.cca.2025.120772_bb1300","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/13543784.2025.2546812","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives","volume":"34","author":"Fiorucci","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb1305","doi-asserted-by":"crossref","first-page":"37","DOI":"10.11648\/j.ijde.20251002.12","article-title":"Role of tirzepatide in obesity management among women with polycystic ovary syndrome","volume":"10","author":"Jannatul","year":"2025","journal-title":"Int. J. Diabetes Endocrinol."},{"key":"10.1016\/j.cca.2025.120772_bb1310","series-title":"Disclosure: Tibb Jacobs declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2025","article-title":"Exenatide. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Karlyle Bistas declares no relevant financial relationships with ineligible companies","author":"Bridges","year":"2025"},{"issue":"11","key":"10.1016\/j.cca.2025.120772_bb1315","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/dia.2011.0050","article-title":"Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes","volume":"13","author":"DeYoung","year":"2011","journal-title":"Diabetes Technol. Ther."},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb1320","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/diabetology6060052","article-title":"Addressing the shortage of GLP-1 RA and dual GIP\/GLP-1 RA-based therapies\u2014a systematic review","volume":"6","author":"Altabas","year":"2025","journal-title":"Diabetology"},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb1325","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13731","article-title":"Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance","volume":"75","author":"Jain","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.cca.2025.120772_bb1330","author":"Scotland N. MSAN"},{"key":"10.1016\/j.cca.2025.120772_bb1335","series-title":"Eperzan (albiglutide): global discontinuation of medicine \u2014 do not initiate new patients; transition all current patients to an alternative therapy by July 2018","author":"Ltd","year":"2017"},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb1340","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2337\/dc12-0709","article-title":"The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cca.2025.120772_bb1345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5604\/01.3001.0054.8367","article-title":"Triple agonists of GIP, GLP-1, and glucagon - the future of obesity treatment: a review of the latest findings","volume":"18","author":"Brzd\u0119k","year":"2024","journal-title":"Med. Sci. Pulse"},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb1350","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41421-024-00700-0","article-title":"Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide","volume":"10","author":"Li","year":"2024","journal-title":"Cell Discov."},{"issue":"10401","key":"10.1016\/j.cca.2025.120772_bb1355","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb1360","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb1365","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/biom15060796","article-title":"Retatrutide\u2014A game changer in obesity pharmacotherapy","volume":"15","author":"Katsi","year":"2025","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb1370","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat. Metab."},{"issue":"9","key":"10.1016\/j.cca.2025.120772_bb1375","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-monthly maridebart cafraglutide for the treatment of obesity \u2014 a phase 2 trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"10403","key":"10.1016\/j.cca.2025.120772_bb1380","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cca.2025.120772_bb1385","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2025.120772_bb1390","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105862","article-title":"The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats","volume":"118","author":"Kuhre","year":"2025","journal-title":"eBioMedicine"},{"issue":"10499","key":"10.1016\/j.cca.2025.120772_bb1395","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study","volume":"406","author":"Dahl","year":"2025","journal-title":"Lancet"},{"issue":"10499","key":"10.1016\/j.cca.2025.120772_bb1400","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(25)01176-6","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Gasiorek","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2025.120772_bb1405","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101633","article-title":"BI 456906: Discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy","volume":"66","author":"Zimmermann","year":"2022","journal-title":"Mol Metab."},{"key":"10.1016\/j.cca.2025.120772_bb1410","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110779","article-title":"Perspectives in weight control in diabetes \u2013 Survodutide","volume":"207","author":"Klein","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb1415","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb1420","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bl\u00fcher","year":"2024","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb1425","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb1430","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/oby.24184","article-title":"Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE\u2122-1 and -2)","volume":"33","author":"Wharton","year":"2025","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"10.1016\/j.cca.2025.120772_bb1435","first-page":"2101","article-title":"Survodutide for the treatment of obesity: rationale and design of the SYNCHRONIZE cardiovascular outcomes trial","volume":"12","author":"Kosiborod","year":"2024","journal-title":"JACC: Heart Failure."},{"issue":"22","key":"10.1016\/j.cca.2025.120772_bb1440","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-weekly mazdutide in chinese adults with obesity or overweight","volume":"392","author":"Ji","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb1445","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/dc23-1287","article-title":"Efficacy and safety of mazdutide in chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"47","author":"Zhang","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cca.2025.120772_bb1450","series-title":"Innovent\u2019s Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3","author":"Biologics","year":"2025"},{"key":"10.1016\/j.cca.2025.120772_bb1455","series-title":"Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes","author":"Biologics","year":"2025"},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb1460","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1038\/s41598-022-10577-2","article-title":"Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis","volume":"12","author":"Nestor","year":"2022","journal-title":"Sci. Rep."},{"issue":"Supplement_1","key":"10.1016\/j.cca.2025.120772_bb1465","article-title":"262-OR: Pemvidutide, a GLP-1\/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity\u2014A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM)","volume":"73","author":"Aronne","year":"2024","journal-title":"Trial. Diabetes"},{"key":"10.1016\/j.cca.2025.120772_bb1470","series-title":"Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results","author":"Altimmune","year":"2024"},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb1475","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2025.120772_bb1480","unstructured":"Altimmune I. ltimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder(AUD) : Altimmune, Inc; 2024 [Available from: https:\/\/ir.altimmune.com\/news-releases\/news-release-details\/altimmune-announces-fda-fast-track-designation-pemvidutide."},{"key":"10.1016\/j.cca.2025.120772_bb1485","author":"Chakravarthy MVA-T"},{"issue":"Supplement_1","key":"10.1016\/j.cca.2025.120772_bb1490","doi-asserted-by":"crossref","DOI":"10.2337\/db23-75-LB","article-title":"75-LB: CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, is safe, well-tolerated, and produces more than 8% weight loss in four weeks in overweight and obese adults","volume":"72","author":"Chakravarthy","year":"2023","journal-title":"Diabetes"},{"issue":"Supplement_1","key":"10.1016\/j.cca.2025.120772_bb1495","doi-asserted-by":"crossref","DOI":"10.2337\/db25-763-P","article-title":"763-P: Glycemic Control, Weight Reduction, and Safety with CT-388, a Signal-Biased Dual GLP-1\/GIP Receptor Agonist\u2014Results from a 12-Week Cohort in Adults with Obesity and Type 2 Diabetes","volume":"74","author":"Steinberg","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.cca.2025.120772_bb1500","series-title":"[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase Ib results for its dual GLP-1\/GIP receptor agonist CT-388 in people with obesity","author":"Roche","year":"2024"},{"key":"10.1016\/j.cca.2025.120772_bb1505","article-title":"Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity","author":"Roche","year":"2025","journal-title":"Roche"},{"issue":"10","key":"10.1016\/j.cca.2025.120772_bb1510","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","article-title":"Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis","volume":"49","author":"Ismaiel","year":"2025","journal-title":"Int. J. Obes."},{"issue":"18","key":"10.1016\/j.cca.2025.120772_bb1515","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.21037\/atm-21-4162","article-title":"Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data","volume":"9","author":"Zhao","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb1520","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/dom.12640","article-title":"Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide","volume":"18","author":"Milicevic","year":"2016","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb1525","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41387-025-00397-4","article-title":"Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy","volume":"15","author":"Peri","year":"2025","journal-title":"Nutr. Diabetes"},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb1530","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13098-024-01526-2","article-title":"The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study","volume":"16","author":"Gameil","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb1535","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101613","article-title":"Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis","volume":"51","author":"Nassar","year":"2025","journal-title":"Diabetes Metab."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb1540","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/08971900241273188","article-title":"Problematic pharmacokinetics: a case of recurrent pancreatitis post discontinuation of a glucagon-like peptide 1 receptor agonists","volume":"38","author":"Morehouse","year":"2025","journal-title":"J. Pharm. Pract."},{"issue":"11","key":"10.1016\/j.cca.2025.120772_bb1545","doi-asserted-by":"crossref","DOI":"10.3390\/nu14112217","article-title":"The impact once-weekly semaglutide 2.4 mg will have on clinical practice: a focus on the STEP trials","volume":"14","author":"Alabduljabbar","year":"2022","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.cca.2025.120772_bb1550","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26321","article-title":"GLP-1 receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes","volume":"8","author":"Ramsey","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb1555","doi-asserted-by":"crossref","DOI":"10.1111\/jocd.70125","article-title":"Alopecia and semaglutide: connecting the dots for patient safety","volume":"24","author":"Haykal","year":"2025","journal-title":"J. Cosmet. Dermatol."},{"key":"10.1016\/j.cca.2025.120772_bb1560","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdcr.2025.06.012","article-title":"Alopecia areata following semaglutide treatment for weight loss: A case report","volume":"63","author":"Alzahrani","year":"2025","journal-title":"JAAD Case Rep."},{"issue":"3","key":"10.1016\/j.cca.2025.120772_bb1565","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.5586","article-title":"Lifetime health effects and cost-effectiveness of tirzepatide and semaglutide in US adults","volume":"6","author":"Hwang","year":"2025","journal-title":"JAMA Health Forum."},{"key":"10.1016\/j.cca.2025.120772_bb1570","article-title":"Racial and ethnic disparities in prescribing of GLP-1 receptor agonists in the united states: a retrospective cohort analysis","author":"Kukhareva","year":"2024","journal-title":"medRxiv"},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb1575","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2337\/ds19-0031","article-title":"Combining glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors to target multiple organ defects in type 2 diabetes","volume":"33","author":"Anderson","year":"2020","journal-title":"Diabetes Spectr."},{"issue":"11","key":"10.1016\/j.cca.2025.120772_bb1580","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s40265-024-02090-9","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors in Type 2 diabetes: pleiotropic cardiometabolic effects and add-on value of a combined therapy","volume":"84","author":"Scheen","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.cca.2025.120772_bb1585","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.5114\/amsad\/202298","article-title":"Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?","volume":"10","author":"Papaetis","year":"2025","journal-title":"Arch. Med. Sci. Atheroscler. Dis."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb1590","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s43042-025-00686-8","article-title":"Innovative gene therapy strategies for tackling obesity","volume":"26","author":"Sheikh-Hosseini","year":"2025","journal-title":"Egypt. J. Med. Human Gen."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb1595","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s43856-025-00959-8","article-title":"Targeted in vivo gene integration of a secretion-enabled GLP-1 receptor agonist reverses diet-induced non-genetic obesity and pre-diabetes","volume":"5","author":"Hirose","year":"2025","journal-title":"Commun. Med."},{"issue":"5","key":"10.1016\/j.cca.2025.120772_bb1600","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S2213-8587(24)00371-1","article-title":"GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study","volume":"13","author":"Orandi","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.cca.2025.120772_bb1605","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/medicina61010017","article-title":"The beneficial effects of GLP-1 receptor agonists other than their anti-diabetic and anti-obesity properties","volume":"61","author":"Lu","year":"2025","journal-title":"Medicina"},{"issue":"6","key":"10.1016\/j.cca.2025.120772_bb1610","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00125-021-05402-w","article-title":"Pharmacogenetics of novel glucose-lowering drugs","volume":"64","author":"Rathmann","year":"2021","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.cca.2025.120772_bb1615","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1038\/s41591-025-03913-2","article-title":"Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency","volume":"31","author":"Bhatnagar","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.cca.2025.120772_bb1620","article-title":"Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery: a multi-ancestry study in 10 960 individuals from 9 biobanks","author":"German","year":"2025","journal-title":"medRxiv"},{"issue":"12","key":"10.1016\/j.cca.2025.120772_bb1625","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1007\/s40618-025-02700-7","article-title":"Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan","volume":"48","author":"Tuccinardi","year":"2025","journal-title":"J. Endocrinol. Investig."},{"issue":"17","key":"10.1016\/j.cca.2025.120772_bb1630","doi-asserted-by":"crossref","first-page":"9454","DOI":"10.3390\/ijms22179454","article-title":"Circulating microRNAs signature for predicting response to GLP1-RA therapy in Type 2 diabetic patients: a pilot study","volume":"22","author":"Formichi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.cca.2025.120772_bb1635","doi-asserted-by":"crossref","DOI":"10.3390\/nu17081303","article-title":"Effects of GLP-1 analogues and agonists on the gut microbiota: a systematic review","volume":"17","author":"Gofron","year":"2025","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb1640","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with Type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cca.2025.120772_bb1645","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/dom.13186","article-title":"Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment","volume":"20","author":"Jensen","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.cca.2025.120772_bb1650","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125006515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125006515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T14:16:46Z","timestamp":1770733006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898125006515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":328,"alternative-id":["S0009898125006515"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2025.120772","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2025.120772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120772"}}